The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease. (Journal of Clinical Sleep Medicine) Researchers assessed evidence ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

Prazer Therapeutics raises $20M Series B with JJDC's first South Korean investment; Carisma cuts to 6 staff; Cerevance's Parkinson's trial fails; FDA updates for Oncopeptides, Bavarian Nordic ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Westwood Holdings Group (WHG), a publicly traded investment management boutique ...

Dr Morgan reported receiving grants from University of Florida, Cerevance, Cerevel, Intracellular Therapeutics, UCB, Neuraly, and Georgia Memory Net program and consultant/speaker fees from Amneal ...